Navigation Links
BioMarin Corrects Information Included in Bloomberg Article
Date:9/18/2008

NOVATO, Calif., Sept. 18 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today several corrections to an article released by Bloomberg this morning. The article was based on a telephone interview with Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, held on September 17, 2008.

Following is the correct information and is consistent with the information previously released publicly:

-- The Company expects that peak sales of Naglazyme could be $300 million world wide and that the Company expects to be "more than half way there" by next year. That is not intended as sales guidance for 2009.

-- The Company expects that peak sales of Kuvan could be $400 million in the U.S. and that, consistent with other orphan products, could take several years to reach that level. The Company can not predict the exact time to peak sales.

-- The Company has not provided any sales guidance for 2009 or subsequent years. As is the Company's standard practice, it expects that it will provide guidance for 2009 in connection with the release of its full year 2008 financial results in February of 2009.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydroch
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
3. BioMarin to Present at the Citi Biotech Day
4. BioMarin Announces Roll-Out of National PKU Registry
5. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Collins Stewart Growth Conference
7. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
8. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
9. BioMarin to Host Research and Development Day June 5th
10. BioMarin to Present at the Bank of America Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... Nuvilex, Inc. (OTCQB: NVLX) – According to ... are living with diabetes, with  that number expected to ... market for diabetes treatments is approximately $500 billion.  ... from pancreatic cancer.  Pancreatic cancer is the fourth most ... the United States , and according to ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... The Wisconsin Alumni Research Foundation ( WARF ) and ... nutritional supplement manufacturer today with willful and deliberate patent ... , ,The French company, Arkopharma , and its ... the suit when they continued to sell certain products ...
... - The growing body of university research under development beyond ... grow at an even faster pace as the result of ... System presidents and the Wisconsin Alumni Research Foundation. ... for researchers at UW System schools. The focus, however, extends ...
... Lee Dreyfus made a few waves when he suggested ... blue-eyed Arabs of the Upper Midwest" by selling fresh ... many of his ideas, often delivered off-the-cuff to mask ... Dreyfus proposal simultaneously stirred the imagination and set off ...
Cached Biology Technology:WARF sues French company over patent violation 2WiSys to distribute $1 million in research funds 2WiSys to distribute $1 million in research funds 3WiSys to distribute $1 million in research funds 4Fresh water could be a deep economic wellspring for Wisconsin 2Fresh water could be a deep economic wellspring for Wisconsin 3
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
(Date:10/14/2014)... kind of stem cell that can become either a liver ... to a study published today in the journal Stem ... contradicts current theory on how organs arise from cell layers ... and future treatment for, liver cancer., Thanks to stem cells, ... made up of more than 200 cell types. The original, ...
(Date:10/14/2014)... team of scientists led by researchers at the ... University of Miami Miller School of Medicine (UMMSM) ... pathway underlying bipolar (manic depressive) disorder, a breakthrough ... bipolar affective disorder, as well as depression and ... published online this week in Nature Molecular ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... known PSA blood test for prostate cancer in men may ... breast cancer, the most common form of cancer in women ... ACS journal Analytical Chemistry . Chien Chou and ... test also is a potential biomarker of breast cancer in ...
... is available in German and Spanish . ... Chile pose a higher threat to its neighbour, Argentina, than ... of Concepcin in Chile and the Helmholtz Centre for Environmental ... particular, 22 non-native species which occur in Chile on connecting ...
... has shown that light is the key to getting our ... exploring the resynchronisation mechanism in insects has discovered a molecule ... University of London looked at the impact of light on ... flies. They identified a novel molecule, QUASIMODO (QSM), which was ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3Newly discovered molecule essential to resetting 'body clocks' 2
Canine Serum...
NORMAL DONOR DONKEY SERUM...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Biology Products: